Capricor Therapeutics announces promising long-term results for deramiocel deramiocel in Duchenne muscular dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company at the forefront of developing cell and exosome-based therapies, has shared encouraging three-year safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study. The study investigates the effects of deramiocel (CAP-1002), Capricor’s leading therapeutic candidate, on Duchenne muscular dystrophy (DMD), particularly focusing on cardiac aspects […]